Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q4 FY22 results · Jan–Mar 2022
Astec LifeSciences reported revenue from operations of ₹271.98 crore (up 58.2% from Q4 FY21) and net profit of ₹43.06 crore (up 79.7% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 271.98 | 171.92 | +58.2% | 173.35 | +56.9% |
| Other income | 6.80 | 1.55 | +339.4% | 1.96 | +247.2% |
| Total income | 278.79 | 173.47 | +60.7% | 175.31 | +59.0% |
| Profit before tax | 58.30 | 32.18 | +81.2% | 33.21 | +75.6% |
| Net profit for the period | 43.06 | 23.97 | +79.7% | 24.75 | +74.0% |
| Attributable to shareholders of the company | 43.05 | 23.96 | +79.7% | 24.75 | +74.0% |
| EPS, basic (₹) | 21.97 | 12.24 | +79.5% | 12.63 | +74.0% |
| Net margin (%) | 15.8 | 13.9 | 14.3 |
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 271.98 | 171.92 | +58.2% | 173.35 | +56.9% |
| Other income | 6.80 | 1.55 | +339.1% | 1.96 | +247.0% |
| Total income | 278.78 | 173.47 | +60.7% | 175.31 | +59.0% |
| Profit before tax | 58.28 | 32.15 | +81.3% | 33.19 | +75.6% |
| Net profit for the period | 43.04 | 23.94 | +79.8% | 24.74 | +74.0% |
| EPS, basic (₹) | 21.97 | 12.23 | +79.6% | 12.63 | +74.0% |
| Net margin (%) | 15.8 | 13.9 | 14.3 |
Consolidated
- Filed with BSE
- 04 May 2022, 11:40 IST
- Board meeting
- 02 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 04 May 2022, 11:40 IST
- Board meeting
- 02 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE